Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)

NCT ID: NCT05776459

Last Updated: 2026-01-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

210 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-13

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this Phase 2 clinical trial is to evaluate the safety, tolerability and efficacy of AC102 administered as single intratympanic injection compared to oral steroid treatment in patients with Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hearing Loss, Sensorineural

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AC102

AC102 gel and placebo tablets

Group Type EXPERIMENTAL

AC102 gel

Intervention Type DRUG

Drug: AC102 Single intratympanic injection

Placebo Tablets

Intervention Type OTHER

Placebo Tablets taken daily by mouth

Prednisolone

Placebo gel and prednisolone tablets

Group Type ACTIVE_COMPARATOR

Prednisolone

Intervention Type DRUG

Active comparator: Prednisolone Tablets taken daily by mouth

Placebo gel

Intervention Type OTHER

Placebo Single intratympanic injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AC102 gel

Drug: AC102 Single intratympanic injection

Intervention Type DRUG

Prednisolone

Active comparator: Prednisolone Tablets taken daily by mouth

Intervention Type DRUG

Placebo Tablets

Placebo Tablets taken daily by mouth

Intervention Type OTHER

Placebo gel

Placebo Single intratympanic injection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients aged between 18 and 85 years
* Unilateral ISSNHL
* Onset of unilateral ISSNHL between 24 to 120 hours prior to randomization
* An absolute air conduction hearing threshold of at least 65 dB,
* Patients with a relative hearing loss of at least 30 dB compared to the current audiogram of the non-affected ear

Exclusion Criteria

* Insufficient handling of the language used in the speech audiometry tests
* Bilateral hearing loss
* Acute hearing loss from noise trauma, barotrauma or head trauma in either ear at any time
* Congenital hearing loss
* Conductive hearing loss or combined hearing loss determined by a 4PTA \> 10 dB
* History of ISSNHL in the past 1 years in the affected ear
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AudioCure Pharma GmbH

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Reimar Schlingensiepen, MD

Role: STUDY_DIRECTOR

AudioCure Pharma GmbH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universitätsklinik für Hals-, Nasen- und Ohrenheilkunde

Graz, , Austria

Site Status

Ordensklinikum Linz GmbH Barmherzige Schwestern

Linz, , Austria

Site Status

Universitätsklinik für Hals-Nasen-Ohren-Krankheiten

Salzburg, , Austria

Site Status

Universitätsklinik für Hals-, Nasen- und Ohrenkrankheiten

Vienna, , Austria

Site Status

Zdravotnická zařízení Olomouc, ORL

Olomouc, , Czechia

Site Status

Pardubická nemocnice, Klinika ORL a chirurgie hlavy a krku

Pardubice, , Czechia

Site Status

Fakultní nemocnice v Motole

Prague, , Czechia

Site Status

Heilig Geist Hospital

Bensheim, , Germany

Site Status

Klinik für Hals-, Nasen-, Ohrenheilkunde - Charité Campus Benjamin Franklin - HNO Hochschulambulanz

Berlin, , Germany

Site Status

Unfallkrankenhaus Berlin

Berlin, , Germany

Site Status

University Hospital Dresden 'Carl Gustav Carus' - HNO

Dresden, , Germany

Site Status

Klinik und Poliklinik für Hals-, Nasen-, Ohrenkrankheiten, Kopf- und Halschirurgie

Greifswald, , Germany

Site Status

Universitätsklinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Kopf- und Halschirurgie

Halle, , Germany

Site Status

HNO-Praxis Eidelstedter Platz

Hamburg, , Germany

Site Status

Klinik für Hals-, Nasen- und Ohrenheilkunde am Universitätsklinikum

Jena, , Germany

Site Status

Universitätsmedizin der Johannes Gutenberg Universität Mainz Hals-, Nasen-, Ohrenklinik und Poliklinik

Mainz, , Germany

Site Status

Johannes Weseling Clinic Minden

Minden, , Germany

Site Status

Klinikum rechts der Isar

München, , Germany

Site Status

Evangelisches Krankenhaus - Universitätsklinik für HNO

Oldenburg, , Germany

Site Status

Universitätsklinikum Regensburg - Klinik für HNO-Heilkunde

Regensburg, , Germany

Site Status

SRH Zentralklinikum Suhl GmbH

Suhl, , Germany

Site Status

Universitätsklinikum HNO

Würzburg, , Germany

Site Status

Centrum Medyczne Kwiatowa

Bydgoszcz, , Poland

Site Status

Centrum Medyczne MAVIT - Szpital Specjalistyczny Katowice

Katowice, , Poland

Site Status

ALL-MED Cetrum Medyczne

Lodz, , Poland

Site Status

Oddział Laryngologii

Opole, , Poland

Site Status

Kliniczny Szpital Wojewódzki Nr 1 im. Fryderyka Chopina w Rzeszowie

Rzeszów, , Poland

Site Status

Uniwersytecki Szpital Kliniczny Nr 1

Szczecin, , Poland

Site Status

Trialmed

Warsaw, , Poland

Site Status

University Clinical Centre of Serbia

Belgrade, , Serbia

Site Status

Clinical Hospital Centar "dr Dragisa Misovic-Dedinje"

Belgrade, , Serbia

Site Status

Military Medical Academy - ENT department

Belgrade, , Serbia

Site Status

Clinical Hospital Centre Zvezdara

Belgrade, , Serbia

Site Status

Clinical-Hospital Center Zemun

Belgrade, , Serbia

Site Status

Municipal non-profit enterprise Regional Clinical Hospital of Ivano-Frankivsk Regional Council

Ivano-Frankivsk, , Ukraine

Site Status

Communal non-profit enterprise "Central city clinical hospital of Ivano-Frankivsk city council"

Ivano-Frankivsk, , Ukraine

Site Status

Municipal non-profit enterprise Oleksandrivska clinical hospital of Kyiv of the executive body of Kyiv city council

Kyiv, , Ukraine

Site Status

MC Universal Clinic Oberig of Kapytal LLC

Kyiv, , Ukraine

Site Status

LLC Clinic of Healthy Family Astramed

Uzhhorod, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Czechia Germany Poland Serbia Ukraine

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AC102-201

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sudden Deafness Treatment Trial
NCT00097448 COMPLETED PHASE3
Intracochlear Injection of Glucocorticoid
NCT07134075 NOT_YET_RECRUITING PHASE2
FX-322 in Sensorineural Hearing Loss
NCT03616223 COMPLETED PHASE1/PHASE2
Fludrocortisone for Sudden Hearing Loss
NCT01186185 TERMINATED EARLY_PHASE1